Home › Funds › Vestal Point Capital, LP › LXEO

Vestal Point Capital, LP position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

Vestal Point Capital, LP reported holding 4,320,000 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$20.1M, representing 0.47% of its reported portfolio and ranking #45 among its reported holdings. Vestal Point Capital, LP has disclosed LXEO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)4.32M sh
Reported value held$20.11M
Portfolio Weight0.47%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's LXEO position evolved

Vestal Point Capital, LP first disclosed a stake in LXEO in Q1 2024 at 175,000 shares (US$2.7M). The position peaked in Q4 2025 at 4,475,000 shares, worth US$44.4M. Across 10 filings, Vestal Point Capital, LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,320,000 shares valued at US$20.1M — a reduction of -155,000 shares quarter over quarter.. Notable position changes include a 380% increase in Q2 2024 (shares fell 59% over the following quarter), a 41% increase in Q4 2024 (shares fell 47% over the following quarter), a 184% increase in Q2 2025 (shares rose 65% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 175.00K $2.74M New
Q2 2024 840.00K $13.47M Add
Q3 2024 850.00K $7.68M Add
Q4 2024 1.20M $7.90M Add
Q1 2025 1.14M $3.94M Reduce
Q2 2025 3.23M $12.98M Add
Q3 2025 3.25M $21.58M Add
Q4 2025 4.47M $44.44M Add
Q1 2026 4.47M $25.69M Hold
Q2 2026 4.32M $20.11M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has Vestal Point Capital, LP held LXEO?

Vestal Point Capital, LP has disclosed LXEO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Vestal Point Capital, LP's current position in LXEO?

As of Q2 2026, Vestal Point Capital, LP holds 4.32M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $20.11M, representing 0.47% of its reported portfolio and ranking #45.

Has Vestal Point Capital, LP been buying or selling LXEO?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in LXEO. The position peaked in Q4 2025 at 4.47M shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.